Other active comparator
Basal insulin sglt2i
OTHER_ACTIVE_basal_insulin_sglt2i
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Basal bolus insulin | MD -0.09 (-1.14 to 0.93) | 0.43 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Basal bolus insulin | MD -0.10 (-1.07 to 0.89) | 0.45 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Basal bolus insulin | MD -0.90 (-6.10 to 4.27) | 0.29 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Basal bolus insulin | MD -0.88 (-5.63 to 4.35) | 0.29 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Basal bolus insulin | HR 0.37 (0.10 to 1.45) | 0.68 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.60 (0.22 to 12.54) | 0.61 |